Soluble CD30 serum levels before and after treatment with α-interferon in patients with chronic hepatitis C
-
Enrico Di Cesare
Abstract
It has been suggested that soluble CD30 (sCD30) serum levels in chronic hepatitis C are correlated with the activity of the disease and with the outcome of interferon (IFN) treatment. In this study, sCD30 serum levels in 25 patients with chronic hepatitis C, before and after treatment with IFN-2α, were measured. A total of 20 healthy subjects were used as controls. High sCD30 levels in serum were found in 36% of patients and in 5% of controls. In patients with sCD30 levels above or within the normal range, no significant differences in age, gender, serum transaminases and histology activity index were found. In relation to IFN treatment, only responder patients had serum sCD30 higher than controls, although the difference between responders and non-responders was not significant. No changes from baseline values were observed after treatment. Although high, sCD30 serum levels in chronic hepatitis C are not correlated with the disease activity, are not affected by IFN treatment and are not predictors of response to IFN treatment.
References
1. Neumann AU, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–7. 10.1126/science.282.5386.103Search in Google Scholar
2. Quiroga JA, Martin J, Pardo M, Carreno V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig Dis Sci 1999; 39: 2485–96. 10.1007/BF02087671Search in Google Scholar
3. Ferrari C, Urbani S, Penna A, Cavalli A, Valli A, Lamonaca B, et al. Immunopathogenesis of hepatitis C virus infection. J Hepatol 1999; 31(Suppl 1): 31–8. 10.1016/S0168-8278(99)80371-7Search in Google Scholar
4. Reiser M, Marousis CG, Nelson DR, Lauer G, Gonzalez-Peralta RP, Davis GL, et al. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol 1997; 26: 471–8. 10.1016/S0168-8278(97)80409-6Search in Google Scholar
5. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and postreatment with interferon alfa. Hepatology 1996; 24: 6–9. 10.1002/hep.510240102Search in Google Scholar
6. Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Ohmiya M, Tani Y, et al. Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus. Dig Dis Sci 1995; 40: 1837–41. 10.1007/BF02212710Search in Google Scholar
7. Marinho RT, Pinto R, Santos ML, Lobos IV, Moura MC. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. J Viral Hepat 2004; 11: 206–16. 10.1111/j.1365-2893.2004.00496.xSearch in Google Scholar
8. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10: 457–70. 10.1006/smim.1998.0156Search in Google Scholar
9. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elios MM, Zancuoghi G. Preferential expression of CD30 by human CD4+ T cells producing T cytokines. FASEB J 1995; 9: 81–6. 10.1096/fasebj.9.1.7821763Search in Google Scholar
10. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003; 12: 49–61. 10.1016/S0966-3274(03)00014-5Search in Google Scholar
11. Vinante F, Krampera M, Morosato L, Rigo A, Romagnani S, Pizzolo G. Peripheral T lymphocyte cytokine profile (IFN γ, IL-2, IL-4) and CD30 expression/release during measles infection. Haematologica 1999; 84: 683–9. Search in Google Scholar
12. Marshall EK. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000; 156: 1479–84. 10.1016/S0002-9440(10)65018-3Search in Google Scholar
13. Fattovich G, Vinante F, Giustina G, Morosato L, Alberti A, Ruol A, et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996; 103: 105–10. 10.1046/j.1365-2249.1996.915607.xSearch in Google Scholar
14. Foschi FG, Gramenzi A, Castelli E, Cursaro C, Pagani S, Margotti M, et al. Soluble CD30 serum level in HCV-positive chronic active hepatitis: a surrogate marker of disease activity? Cytokine 2000; 12: 815–8. 10.1006/cyto.1999.0653Search in Google Scholar
15. Lee S, Macquillan GC, Keane NM, Flexman J, Jeffrey GP, French MA, et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Immunol Cell Biol 2002; 80: 391–7. 10.1046/j.1440-1711.2002.01102.xSearch in Google Scholar
16. De Lazzari F, Ravagnan P, Tenderini ML, Dicarioto MA, Galliani EA, Lorenzoni U, et al. Circulating solubile-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease. Hepato-Gastroenterology 2002; 49: 231–4. Search in Google Scholar
17. Ishak K, Baptista A, Bianchi L, Callea P, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–9. 10.1016/0168-8278(95)80226-6Search in Google Scholar
18. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25: 449–58. 10.1002/hep.510250233Search in Google Scholar PubMed
19. Woitas RP, Lechmann M, Yung G, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C core-specific peripheral blood T lymphocytes. J Immunol 1997; 159: 1012–8. 10.4049/jimmunol.159.2.1012Search in Google Scholar
20. Latza U, Davis S, Wilhelm D. McKnight B, Seyfarth M, Stein H. Soluble cytokine receptor CD30 in atopic disorders: a case-control study. Clin Exp Allergy 1999; 29: 97–104. 10.1046/j.1365-2222.1999.00450.xSearch in Google Scholar PubMed
21. Okumura M, Hidaka Y, Matsuzuka F, Takeoka K, Tada H, Kuma K, et al. CD30 expression and interleukin-4 and interferon-gamma production of intrathyroidal lymphocytes in Graves' disease. Thyroid 1999; 9: 333–9. 10.1089/thy.1999.9.333Search in Google Scholar PubMed
22. Iwagaki H, Hizuta A, Kohka H, Kobashi K, Nitta Y, Isozaki H, et al. Circulating levels of soluble CD30 and other markers in colorectal cancer patients. J Med 1999; 30: 111–21. Search in Google Scholar
23. Süsal C, Pelzl S, Simon T, Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 2004; 36: 29–34. 10.1016/j.transproceed.2003.11.019Search in Google Scholar PubMed
©2005 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background
- Detection of brain injury by fatty acid-binding proteins
- High-throughput scanning of breast tumor surgical specimens for low-level mutations
- Cardiovascular risk-associated allele frequencies for 15 genes in healthy elderly French and Chinese
- Soluble CD30 serum levels before and after treatment with α-interferon in patients with chronic hepatitis C
- Development, validation and evaluation of a homogenous one-step reverse transcriptase-initiated PCR assay with competitive internal control for the detection of hepatitis C virus RNA
- Counteracting adriamycin-induced oxidative stress by administration of N-acetyl cysteine and vitamin E
- Comparative analysis of the DNA staining efficiencies of different fluorescent dyes in preparative agarose gel electrophoresis
- Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma
- Measurement of troponin I 48h after admission as a tool to rule out impaired left ventricular function in patients with a first myocardial infarction
- The efficacy of cystatin C assay in the prediction of glomerular filtration rate. Is it a more reliable marker for renal failure?
- Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation
- Influence of short-term venous stasis on clinical chemistry testing
- Educational intervention together with an on-line quality control program achieve recommended analytical goals for bedside blood glucose monitoring in a 1200-bed university hospital
- The reliability of calculated laboratory results
- Preliminary evaluation of the performance of a new, highly sensitive commercial immunoassay for serum ferritin determination
- Importance of the detection method for intact dimeric human chorionic gonadotropin without interference with the free human chorionic gonadotropin β subunit for pregnancy exclusion before liver transplantation in a woman with cholangiocarcinoma
- Comparison of Liaison N-tact PTH (Diasorin) and N-tact PTH SP IRMA (Diasorin) in hemodialyzed patients
Articles in the same Issue
- Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background
- Detection of brain injury by fatty acid-binding proteins
- High-throughput scanning of breast tumor surgical specimens for low-level mutations
- Cardiovascular risk-associated allele frequencies for 15 genes in healthy elderly French and Chinese
- Soluble CD30 serum levels before and after treatment with α-interferon in patients with chronic hepatitis C
- Development, validation and evaluation of a homogenous one-step reverse transcriptase-initiated PCR assay with competitive internal control for the detection of hepatitis C virus RNA
- Counteracting adriamycin-induced oxidative stress by administration of N-acetyl cysteine and vitamin E
- Comparative analysis of the DNA staining efficiencies of different fluorescent dyes in preparative agarose gel electrophoresis
- Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma
- Measurement of troponin I 48h after admission as a tool to rule out impaired left ventricular function in patients with a first myocardial infarction
- The efficacy of cystatin C assay in the prediction of glomerular filtration rate. Is it a more reliable marker for renal failure?
- Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation
- Influence of short-term venous stasis on clinical chemistry testing
- Educational intervention together with an on-line quality control program achieve recommended analytical goals for bedside blood glucose monitoring in a 1200-bed university hospital
- The reliability of calculated laboratory results
- Preliminary evaluation of the performance of a new, highly sensitive commercial immunoassay for serum ferritin determination
- Importance of the detection method for intact dimeric human chorionic gonadotropin without interference with the free human chorionic gonadotropin β subunit for pregnancy exclusion before liver transplantation in a woman with cholangiocarcinoma
- Comparison of Liaison N-tact PTH (Diasorin) and N-tact PTH SP IRMA (Diasorin) in hemodialyzed patients
